Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
grade B 11.65 -2.92% -0.35
CORT closed down 2.92 percent on Friday, April 3, 2020, on approximately normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical CORT trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bearish Engulfing Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Overbought Stochastic Strength -2.92%
Upper Bollinger Band Touch Strength -2.92%
NR7 Range Contraction -0.34%
NR7-2 Range Contraction -0.34%
Stochastic Reached Overbought Strength -0.34%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Pharmaceutical Organ Systems Surgery Disorders Endocrine System Diabetes Mellitus Hormones Depression Cushing's Syndrome Corcept Therapeutics Hyperglycemia Cortisol Endogenous Cushing's Syndrome

Is CORT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.48
52 Week Low 9.55
Average Volume 1,170,209
200-Day Moving Average 12.77
50-Day Moving Average 12.32
20-Day Moving Average 10.99
10-Day Moving Average 11.29
Average True Range 0.89
ADX 20.28
+DI 23.53
-DI 16.20
Chandelier Exit (Long, 3 ATRs ) 10.13
Chandelier Exit (Short, 3 ATRs ) 12.38
Upper Bollinger Band 12.11
Lower Bollinger Band 9.87
Percent B (%b) 0.79
BandWidth 20.35
MACD Line -0.15
MACD Signal Line -0.36
MACD Histogram 0.2101
Fundamentals Value
Market Cap 1.32 Billion
Num Shares 113 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 58.25
Price-to-Sales 19.04
Price-to-Book 31.30
PEG Ratio 0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.03
Resistance 3 (R3) 13.16 12.82 12.80
Resistance 2 (R2) 12.82 12.47 12.76 12.72
Resistance 1 (R1) 12.24 12.25 12.07 12.11 12.65
Pivot Point 11.90 11.90 11.82 11.84 11.90
Support 1 (S1) 11.32 11.55 11.15 11.19 10.65
Support 2 (S2) 10.98 11.33 10.92 10.58
Support 3 (S3) 10.40 10.98 10.50
Support 4 (S4) 10.27